Metsera in our Pivotal Point Check: What Makes the Young Biotech Company so Attractive to Pfizer? The Acquisition Provides the Pharma Giant Access to a $150 Billion Market for Obesity Drugs!

Metsera is a young biotech company focused on developing drugs for the treatment of obesity and metabolic disorders. The drug, MET-097i, showed comparable weight loss in early clinical trials to leading GLP-1-based therapies. Analysts see significant potential in the obesity drug market, which is expected to grow to $150 billion by 2030.  On Monday, September 22, the biotech company Metsera surprised the stock market. The stock price rose by nearly 60%. This massive jump followed the announcement of a takeover by the pharmaceutical...